Organoid optimization: Engineering a better cell therapy to treat type 1 diabetes

2020 ◽  
Vol 12 (526) ◽  
pp. eaba2909
Author(s):  
Jessica D. Weaver

Islet organoids reaggregated in endothelialized collagen constructs improve engraftment and function in the subcutaneous space in diabetic mice.

2009 ◽  
Vol 3 (6) ◽  
pp. 511-518
Author(s):  
I. B. Sokolova
Keyword(s):  

PLoS ONE ◽  
2013 ◽  
Vol 8 (11) ◽  
pp. e78687 ◽  
Author(s):  
Eric V. Marietta ◽  
Andres M. Gomez ◽  
Carl Yeoman ◽  
Ashenafi Y. Tilahun ◽  
Chad R. Clark ◽  
...  

Cells ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1589
Author(s):  
Ryota Inoue ◽  
Kuniyuki Nishiyama ◽  
Jinghe Li ◽  
Daisuke Miyashita ◽  
Masato Ono ◽  
...  

Stem cell therapy using islet-like insulin-producing cells derived from human pluripotent stem cells has the potential to allow patients with type 1 diabetes to withdraw from insulin therapy. However, several issues exist regarding the use of stem cell therapy to treat type 1 diabetes. In this review, we will focus on the following topics: (1) autoimmune responses during the autologous transplantation of stem cell-derived islet cells, (2) a comparison of stem cell therapy with insulin injection therapy, (3) the impact of the islet microenvironment on stem cell-derived islet cells, and (4) the cost-effectiveness of stem cell-derived islet cell transplantation. Based on these various viewpoints, we will discuss what is required to perform stem cell therapy for patients with type 1 diabetes.


2009 ◽  
Vol 35 (2) ◽  
pp. 85-93 ◽  
Author(s):  
L. Vija ◽  
D. Farge ◽  
J.-F. Gautier ◽  
P. Vexiau ◽  
C. Dumitrache ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document